MAPK10 and hepatocellular carcinoma: Consistently, statistical analysis confirmed that HCC patients with medium immune activity had significantly higher expression of MAPK10 than those with low immune activity (Wilcoxon Test, P < 0.01; Figure 3G), while HCC patients with medium immune activity had a significantly lower expression of MAPK10 compared to patients with high immune activity (Wilcoxon Test, P < 0.001; Figure 3G).